Dr. George on Radium-223 for Patients With mCRPC, Part II


For High-Definition, Click

Daniel J. George, MD, Director of Genitourinary Oncology, Duke Cancer Institute, discusses how radium-223 is used to treat patients with metastatic castration-resistant prostate cancer.

Patients with pain caused by inflammation of bony metastases are ideal candidates for radium-223, George says, and they do not have to be on narcotics to qualify.

George says radium-223 will also work in patients that have asymptomatic bony lesions. Future studies will take place to see if radium-223 can be used in combination with other hormonal therapies, immunotherapies, or targeted therapies. Radium-223 is also being mixed with different chemotherapy combinations, which could add an overall benefit for the patients, George says.

With the approval of radium-223, George says, there are now a number of different therapies and different actions of therapies that will prolong survival. Radium-223 lends itself to be used in combinations and can be used in different approaches, which is very helpful for a patient population whose estimated median survival is approximately three years. Radium-223 lends itself to be used in combinations because it is easy to use and has a relatively low toxicity profile.

George says there will be studies done in the future to find out where radium-223 fits in, but he believes that it will probably be an alternative to docetaxel.

Related Videos
Timothy Yap, MBBS, PhD, FRCP
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Kara N. Maxwell, MD, PhD